The blood-brain barrier as a target for pharmacological modulation

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 2, 1999, Pages 162-167

  Bartus, Raymond T ^a  

^a ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ RECEPTOR; BRADYKININ RECEPTOR AGONIST; IRON; LOBRADIMIL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX 26; NERVE GROWTH FACTOR; TRANSFERRIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CLINICAL TRIAL; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; GLIOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN;

EID: 0032918148     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Pardridge WM: Drug delivery to the brain. J Cereb Blood Flow Metab (1997) 17:713-731. A very good overview of the obstacles presented by the EBB and several approaches to facilitating delivery of drugs across the barrier.
2. Rapoport SI: Modulation of blood-brain barrier permeability. J Drug Target (1996) 3:417-425. Good review of delivery approaches, focusing on the osmostic method by a pioneer in the field.
3. Neuwelt EA, Rapoport SI: Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. FedP/oc(1984) 43:214-219.
4. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 42:1083-1100. Most comprehensive overview of data supporting the osmotic method by the researchers who have published the majority of work on this approach.
5. Kessler R, Goble J, Bird J, Girton M, Doppman J, Rapoport S, Barranger J: Measurement of blood-brain barrier permeability with positron emission tomography and [Ga] EDTA. J Cereb Blood Flow Metab (1984) 4:323-332.
6. Zunkeler B, Carson RE, Oison J, Blasberg RG, Girton M, Bacher J, Herscovitch P, Oldfield EH: Hyperosmolar bloodbrain barrier disruption in baboons: an in vivo study using positron emission tomography and rubidium-82. J Neurosurg (1996) 84:494-502.
7. Zünkeler B, Carson RE, Oison J, DeVroom H, Lutz RJ, Blasberg RG, Wright DC. Dedrick RL, Kämmerer W, Patronas NJ, Herscovitch P, Oldfield EH: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg (1996) 85:1056-1065.
8. Krall RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA: Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery (1998) 43:879-886.
9. Weyerbrook A, Oldfield E: Comment on 'Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model'. Neurosurgery (1998) 43:887-889.
10. Raymond J, Robertson D, Dinsdale H: Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci (1986) 13:214-222.
11. Wahl M, Unterberg A, Whalley ET, Bacthmann A, Young AR, Edvinsson L, Wagner FFW: Effects of bradykinin on cerebral haemodynamics and blood-brain barrier function. In: Peptidergic Mechanisms in the Cerebral Circulation. Edvinsson L (Ed), Chichester, Norwood (1987) 166-190.
12. Inamura T, Black KL: Bradykinin selectively opens bloodtumor barrier in experimental brain tumors. J Cereb Blood FlowMetab (1994) 14:862-870. Seminal paper demonstrating that systemic bradykinin can increase permeability of the BBTB.
13. Nomura T, Inamura T, Black KL: Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res (1994) 659:62-66.
14. Doctrow SR, Abelleira SM, Curry LA, Heller-Harrison R, Kozarich JW, Malfroy B, McCarroll LA, Morgan KG, Morrow AR, Musso GF: The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp T/7er(1994) 271:229-237.
15. Bartus RT, Elliott PJ, Hayward NJ, Dean RL, McEwen E, Fisher SK: Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology (1996) 33:270-278. First evidence that Cereport can increase permeability of brain tissue outside the tumor barrier. Also demonstrated dose response, with increasing doses producing increasingly greater permeabilty effects. Finally, demonstrated that these effects were mediated specifically through B, receptors.
16. Sträub JA, Akiyama A, Parmar P: In vitro plasma metabolism of RMP-7. Pharm Fies (1994) 11:1673-1676.
17. Inamura T, Nomura T, Bartus RT, Black KL: Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg (1994) 81:752-758. First paper to demonstrate in vivo efficacy of the novel bradykinin agonist, Cereport, using a rat glioma model. Increased permeability of the BBTB was demonstrated for a wide range of molecular weight compounds.
18. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL: Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery (1996) 39:125-134.
19. Dean RL, Elliott PJ, Nagle T, Hayward N, Merchant R, Bartus R: RMP-7 increases uptake of caboplatin into rat gliomas: Comparison of three cell lines. In: American Association for Cancer Research, 20-24 April 1996, Washington, DC, USA. Abstract No 2063.
20. Elliott PJ, Hayward NJ, Huff MR, Nagle TL, Black KL, Bartus RT: Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy. Exp Neural (1996) 141:214-224.
21. Bartus RT, Elliott PJ, Dean RL, Hayward NJ, Nagle TL, Huff MR, Snodgrass PA, Blunt DG: Controlled modulation of BBS permeability using the bradykinin agonist, RMP-7. Exp Neural (1996) 142:14-28.
22. Elliott PJ, Hayward NJ, Dean RL, Blunt DG, Bartus RT: Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res (1996) 56:3998-4005. Initial, clear evidence that iv administration of Cereport can reliably increase permeability of the BBTB. This occurred in a dose-related fashion. Similar, though lesser changes were also seen in areas outside the tumor boundary.
23. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW: Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res (1995) 705:125-135. Quantitative electron microscopy study demonstrating that iv Cereport can increase permeability of non-tumor BBB. Additionally, it demonstrates that the physical mechanism of action is through opening tight junctions, producing an aqueous corridor for diffusion of water-soluble compounds from the blood to the brain. No evidence of changes in intraendothelial transport was observed.
24. Emerich D, Snodgrass P, Pink M, Bloom F, Bartus R: Central analgesic actions of loperamide following transient permeation of the blood brain barrier with Cereport (RMP7). Brain Res (1998) 801:259-266.
25. Nakano S, Matsukado K, Black KL: Enhanced cytokines delivery and intercellular adhesion molecule 1 (ICAM-1) expression in glioma by intracarotid infusion of bradykinin analog, RMP-7. Neurol Res( 1997) 19:501-508.
26. Barth R, Yang W, Moeschberger M, Goodman J, Bartus R: Enhanced delivery of boronophenylalanine for neutron capture therapy of brain tumors using the bradykinin analogue, Cereport (RMP-7). Neurosurgery (1999) 44:351360.
27. Barth R, Yang W, Rotaru J, Moeschberger M, Joel D, Nawrocky M, Goodman J, Soloway A: Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res (1997) 57:1129-1136.
28. Yang W, Barth R, Rotaru J, Coderre J, Nawrocky M, Bartus R: Enhanced uptake of boronophenylalanine and efficacy of BNCT in F98 glioma-bearing rats following administration of Cereport. In: Frontiers in Neutron Capture Therapy, Hawthorne MF, Shelley K, Wiersma R (Eds), Plenum Press (1999). In press.
29. Black K: Comment on 'Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model'. Neurosurgery (1998) 43:887.
30. Bruce J: Comment on 'Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model'. Neurosurgery (1998) 43:889.
31. Greenberg H: Comment on 'Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model'. Neurosurgery (1998) 43:886-887.
32. Piepmeier J: Comment on 'Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model'. Neurosurgery (1998) 43:887.
33. Black KL, Cloughesy T, Huang SC, Gobin YP, Zhou Y, Grous J, Nelson G, Farahani K, Höh CK, Phelps M: Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg (1997) 86:603-609. Initial evidence for increased permeability effects of Cereport in humans.
34. Cloughesy T, Black K, Gobin Y, Farahani K, Nelson G, Villablanca P, Kabbinavar F, Vinuela F, Wortel C: Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery (1999) 44:270-278.
35. Bartus R, Snodgrass P, Dean R, Kirn B, Black K, Emerich D: Use of Cereport (RMP-7) to increase delivery of carboplatin to gliomas: Insight and parameters for intracarotid infusion via a single-lumen cannula. Drug Delivery (1999) 6:15-23.
36. Matsukado K, Nakano S, Bartus RT, Black KL: Steroids decrease uptake of carboplatin in rat gliomas - Uptake improved by intracarotid infusion of bradykinin analog, RMP-7. JNeuroncot (1997) 34:131-138.
37. Riley MG, Kim NN, Watson VE, Gobin YP, LeBel CP, Black KL, Bartus RT: Intra-arterial administration of carboplatin and the BBB permeabilizing agent, RMP-7: A toxicological evaluation in Swine. J A/euranco/(1998) 36:167-178.
38. Ford JM, Miles KA, Hayball MP, Bearcroft PW, Bleehen NM, Osbom CS: A simplified technique for measurment of blood-brain barrier permeability using CT: preliminary results of the effect of RMP-7. In: Quantitative Imaging in Oncology Faulkner K (Ed). London British Institute of Radiology, (1996):126-155.
39. LeMay DR, Kittaka M, Gordon EM, Gray B, Stins MF, McComb JG, Jovanovic S, Tabrizi P, Weiss MH, Bartus R, Anderson WF, Zlokovic BV: Intravenous RMP-7 increases delivery of glancovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy. Hum Gene T/7er(1998) 9:989-995.
40. Emerich D, Snodgrass P, Dean R, Agostino M, Hasler B, Pink M, Xiong H, Su Kim B, Bartus R: Enhanced uptake of carboplatin into brain tumors with intravenous Cereport (RMP-7): Dramatic differences as a function of dosing parameters. BritJ Cancer(1999). In press.
41. Nakano S, Matsukado K, Black KL: Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res (1996) 56:4027-4031. Evidence that bradykinin's effects on barrier permeability mediated through nitrous oxide (NO) pathway.
42. Matsukado K, Sugita M, Black KL: Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B, receptors in malignant gliomas. Brain Res (1998) 792:10-15.
43. Sugita M, Black KL: Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors. Cancer Res (1998) 58:914-920. Further evidence for importance of NO pathway in bradykinin's effects on BBB; paper also demonstrates enhanced effects of bradykinin by pharmacologically inhibiting PDEV with Zaprinast to prolong cGMP (the second messenger induced in NO pathway).
44. Sugita M, Hunt G, Liu Y, Black KL: Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin. A/euro/ Res (1998) 20:559-563.
45. Elliott PJ, Hayward NJ, Dean RL, Bartus RT: Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist RMP-7. Immunopharmacology (1996) 33:205-208.
46. Fike JR, Gobbel GT, Mesiwala AH, Shin HJ, Nakagawa M, Lambom KR, Seilhan TM, Elliott PJ: Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain. J Neuroncol (1998) 37:199-215.
47. Pardridgo WM: New approaches to drug delivery through the blood-brain barrier. Trends Biotechno! (1994) 12:239-245.
48. Partridge WM: Vector-mediated peptide drug targeting to the brain. In: Peptide and Protein Drug Delivery, Alfred Benzon Symposium 43, Frokjaer S (Ed). Copenhagen (1998):381-392.
49. Pardridge WM: CNS drug design based on principles of bloodbrain barrier transport J Neurochem (1998) 70:1781-1792.
50. Granholm AC, Albeck G, Backman C, Curtis M, Ebenda! T, Friden P, Henry M, Hoffer B, Kordower J, Rose GM, Söderström S, Bartus RT: A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review. Rev Neurosci (1998) 9:31-55.
51. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granholm AC: Blood brain barrier penetration and in vivo activity of an NGF conjugate. Science (1993) 259:373-377.
52. Kordower JH, Charles V, Bayer R, Bartus RT, Putney S, Walus LR, Friden PM: Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc Natl Acad Sci USA (1994) 91:9077-9080. Seminal paper demonstrating that a transferrin carrier system can delivery iv administered NGF to adult brain to induce trophic effect (ie, protection of cholinergic neurons in strialum from glutamate toxicity).
53. Charles V, Mufson EJ, Friden PM, Bartus RT, Kordower JH: Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res (1996) 728:193-203.
54. Dean R, Stackman R, Abelliera S, Carroll R, Kordower J, Walsh T, Bartus RT: NGF conjugate ameliorates basal forebrain cholinergic hypofunction induced by AF64A. Abstr Neurosci (1994) 20:1103.
55. Backman C, Rose GM, Bartus RT, Hoffer BJ, Henry MA, Friden PM, Granholm AC: Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J Neurosci (1996) 16:5437-5442. Clear evidence for biological response to iv administered NGF in aged rats, improving both condition of basal forebrain cholinergic neurons, but also performance on memory task.
56. Backman C, Rose GM, Bartus RT, Hoffer BJ, Mufson EJ, Granholm AC: Carrier-mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors. J CompNeurol (1997) 387:1-11.
57. Markowsa A, Koliastos V, Breckler S, Price D, Olton D: Human nerve growth factor improves spatial memory in aged but not in young rats. J Neurosci (1994) 14:4815-4824.
58. Markowska AL, Price D, Koliatsos VE: Selective effects of nerve growth factor on spatial recent memory as assessed by a delayed nonmatching-to-position task in the water maze. J Neurosci (1996) 16:3541-3548.
59. Hefti F: Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transection. J Neurosci (1986)6:2155-2162.
60. Albeck DS, Hoffer BJ, Quissell D, Sanders LA, Zerbe G, Granholm AC: A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport (1997) 8:2293-2298.
61. Wu D, Pardridge W: Neuroprotection with noninvasive neurotrophin delivery to the brain. Neumbiology (1999) 96:254-259. Evidence that iv BDNF can also be delivered to brain via transferrin carrier system and that protection against acute neurodegeneration (global ischemia) can be achieved.
62. Wu D, Yang J, Pardridge W: Drug targeting of a peptide radiopharmaceutjcal through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest (1997) 100:1804-1812. Initial evidence for increased delivery via active receptor mediated transport in non-human primates. Also, used insulin transport system, which is reported to be significantly more efficient than transferrin.
63. Sanovich E, Le H, Bartus R, Dean R, Ellioil P, Brightman M: RMP-7, a bradykinin analog, permeabilizes blood vessels in a rat brain tumor. Soc Neurose/ (1996) 22:774.
64. Dean R, Emerich D, Marsh J, Hasler B, Agostino M, Lafreniere D, Snodgrass P, Xiong H, Bartus R: Cereport increases uptake of carboplatin in a rat model of cerebral metastatic tumors. AbstrSoc A/euro (1998) 24:2160.
65. Backman C, Biddle PT, Ebenda! T, Friden PM, Gerhardt GA, Henry MA, Mackerlova L, Soderstrom S, Stromberg I, Walus L, Hoffer BJ, Granholm AC: Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo. Exp Neural (1995) 132:1-15.
66. 3H]-biotinylaed phosphorothioate oligodepxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther (1996) 276:206-211.